PandemiCure's NanoMed research track explores nanotechnology applications in three investable, FDA-navigable lanes: nano-enabled diagnostics (better lateral flow capture, fluorescent biosensors), nano-enabled drug delivery (lipid nanoparticles, targeted release), and nano-enabled PPE and antimicrobial surfaces. All development is regulatory-pathway aware from day one.
Lane 1 — Nano-Enabled Diagnostics
- Functionalized nanoparticle capture surfaces for lateral flow assays
- Quantum dot fluorescent tags for higher-sensitivity rapid tests
- Gold nanoparticle signal amplification for low-viral-load detection
- Nano-biosensor coatings for AirSentinel bioaerosol detection module
- SurfaceSentinel nano-swab enhanced ATP and pathogen capture
Lane 2 — Nano-Enabled Drug Delivery
- Lipid nanoparticle (LNP) formulation support for mRNA and nucleic acid therapeutics
- Targeted nanoparticle delivery for antiviral compounds — reduced systemic toxicity
- Controlled-release nanocapsule formulations for long-acting prophylactics
- Collaboration with CounterMeasure Studio for LNP manufacturing readiness scoring
Lane 3 — Nano-Enabled PPE & Surfaces
- Antimicrobial nanocoatings for hospital surfaces, ambulance interiors, and HVAC surfaces
- Nano-fiber filtration enhancement for N95 and elastomeric respirator media
- Self-decontaminating surface materials for BioResponse Trailer interior
- VitalSurface nano-antimicrobial hospital bed application extension
FDA Regulatory Path
- FDA guidance: Drug Products, Including Biological Products, that Contain Nanomaterials
- Product-specific safety and effectiveness review under existing statutory authorities
- CDER and CBER review pathways depending on product classification
- Nano-enabled diagnostics — FDA 510(k) De Novo pathway coordination
- Nano-surface materials — EPA antimicrobial registration where applicable
Collaborate on NanoMed Track
Research partnerships, data-sharing agreements, and co-development opportunities are available. Contact the PandemiCure team to explore.
Contact Us →